|Bid||141.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||155.30 - 158.02|
|52 Week Range||104.90 - 164.13|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||128.80|
|Earnings Date||Jul 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||170.31|
Ari Bousbib became the CEO of IQVIA Holdings Inc. (NYSE:IQV) in 2016. This report will, first, examine the CEO...
Robert Half's (RHI) second-quarter 2019 revenues are expected to benefit from strength in staffing and Protiviti operations.
IQVIA (IQV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Martin Marietta Materials, Inc. (MLM) today announced the appointment of Thomas (Tom) H. Pike as an independent member to its Board of Directors, effective July 15, 2019. With Mr. Pike’s appointment, the Martin Marietta Board is comprised of 10 directors, five of whom have joined since 2016. Mr. Pike will serve on Martin Marietta’s Management Development and Compensation Committee.
IQVIA (IQV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IQVIA Holdings Inc. , will announce its second-quarter 2019 financial results before the market opens on Wednesday, July 24, 2019. The IQVIA management team will also host a conference call and webcast at 9:00 a.m.
VANCOUVER , July 8, 2019 /CNW/ - Nextleaf Solutions Ltd. ("Nextleaf", "OILS" or the "Company") (CSE: OILS) (OTC: OILFF) ( Frankfurt : L0MA) today announced that it has added Mr. Tim Gillis to its Board of Directors, effective immediately. Mr. Gillis most recently led STI Technologies Limited ("STI"), a leading healthcare technology company which connects physicians, patients, pharmacy and pharma with a variety of intelligent reimbursement solutions that empower choice amongst healthcare professionals and patients, ultimately improving patient outcomes. As Chief Executive Officer, Mr. Gillis navigated STI through a period of hypergrowth which culminated in a sale to IQVIA (IQV).
Belong.Life, a U.S.-Israeli creator of a social network and app for cancer patients, said on Monday it raised $14 million in a funding round led by life science analytics firm IQVIA. It is also investing in a new platform designed to improve patient engagement, education, compliance and satisfaction. The funding round included The Group Ventures and existing investors.
Disruptive tech simplifies patient engagement and amplifies patients’ voices to advance outcomes for life science companies
Summer is here (June 21 is the first day of summer solstice). You might be tempted to ditch the stock market and take the next three months off. But you if you do, you'll miss some sizzling summer-stock action.
IQVIA™ (IQV) today announced that Chiesi Farmaceutici, the international research-focused healthcare Group (Chiesi Group) is leveraging IQVIA Technologies’ Orchestrated Customer Engagement (OCE) technology platform to enhance customer proximity and teamwork effectiveness in more than 20 markets, including the U.S., China, Germany, U.K., France, Spain, Italy, Russia and Brazil.
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 8 months is one of those periods, as the Russell 2000 […]
Italian multinational pharmaceutical company to coordinate all physical and digital activities with pharmacists using IQVIA Technologies’ end-to-end solution. IQVIA™ (IQV) today announced that Zambon, an Italian multinational pharmaceutical and fine-chemical company, has selected Orchestrated Customer Engagement (OCE), IQVIA Technologies’ transformative commercial engagement technology, to maximize customer interactions and to make a real impact within the retail channel.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Previously announced FDA approval of IBRANCE® for the treatment of men with metastatic breast cancer based in part on IQVIA real world analytics; Pfizer Oncology to p